section name header

Footnotes

a Tested in dextrose 5%.

b Tested in sodium chloride 0.9%.

c Tested in both dextrose 5% and sodium chloride 0.9%.

d Test performed using the formulation WITHOUT edetate disodium.

e Tested using Baxter Healthcare premixed nitroglycerin infusion in dextrose 5% with citrate buffer.

f Refer to Appendix for the composition of parenteral nutrition solutions. TNA indicates a 3-in-1 admixture, and TPN indicates a 2-in-1 admixture.

g Tested in dextrose 5% in sodium chloride 0.225%.

h Ceftolozane component. Ceftolozane in a 2:1 fixed-ratio concentration with tazobactam.

i Meropenem component. Meropenem in a 1:1 fixed-ratio concentration with vaborbactam.

j Test performed using the formulation WITH edetate disodium.

k Imipenem component. Imipenem in a 2:2:1 fixed-ratio concentration with cilastatin and relebactam.

l Tested with dopamine HCl (DCC) 3.2 mg/mL.

m Tested with lidocaine HCl (AB) 8 mg/mL.

n Tested with sodium nitroprusside (ES) 0.4 mg/mL.

o Tested with dobutamine HCl (LI) 4 mg/mL.

p Tested as the premixed infusion solution.

q Sulbactam component. Sulbactam in a 1:1 fixed-ratio concentration with durlobactam.